1. A 74-year-old man with HFrEF (LVEF 27%) on furosemide 80 mg daily and empagliflozin 10 mg daily presents for routine follow-up. His weight is down 4.1 kg since starting empagliflozin 6 weeks ago, his creatinine has risen from 1.1 to 1.6 mg/dL, and his eGFR (estimated glomerular filtration rate — a measure of kidney function) has fallen from 64 to 44 mL/min/1.73m². He is asymptomatic, blood pressure is 108/66 mmHg, and his JVP (jugular venous pressure — a bedside measure of central venous filling pressure) is flat. Which of the following best represents the correct interpretation of this presentation and the appropriate management?
A) The creatinine rise represents empagliflozin-induced acute tubular necrosis — SGLT2 inhibitors cause direct proximal tubular toxicity when the eGFR falls below 50 mL/min/1.73m² and empagliflozin must be discontinued immediately with nephrology consultation to prevent progression to dialysis-dependent renal failure
B) The creatinine rise is an expected hemodynamic effect of SGLT2 inhibitors on glomerular filtration — similar to the initial creatinine rise seen with ACE inhibitors, a modest functional decline in eGFR at initiation is a class effect that predicts long-term renoprotection and should not prompt any change in management
C) This presentation is consistent with volume depletion from additive diuresis — the weight loss, flat JVP, low-normal blood pressure, and rising creatinine in a patient on both a loop diuretic and an SGLT2 inhibitor indicate hemodynamically-mediated (prerenal) azotemia; the appropriate response is to reduce the furosemide dose, not to discontinue empagliflozin, as restoring volume balance will likely normalize the creatinine
D) The creatinine rise represents contrast nephropathy from a recent imaging study that coincided with empagliflozin initiation — the combination of iodinated contrast and SGLT2 inhibitor-mediated reduction in renal autoregulation creates a nephrotoxic synergy; empagliflozin must be held and restarted only after creatinine returns to baseline
E) The creatinine rise is expected and mandates no change — an eGFR decline to 44 mL/min/1.73m² is within the approved range for empagliflozin in the heart failure indication and the furosemide dose should be increased to counteract the SGLT2 inhibitor-mediated reduction in loop diuretic efficacy that occurs at lower eGFR values
ANSWER: C
Rationale:
The clinical picture is classic for volume depletion from additive diuresis: 4.1 kg weight loss, flat JVP (absent venous congestion), low-normal blood pressure at 108/66 mmHg, and a creatinine rise from 1.1 to 1.6 mg/dL in a patient simultaneously on furosemide 80 mg daily (a loop diuretic) and empagliflozin 10 mg daily (which adds osmotic diuresis from glucosuria). The rising creatinine in this context is prerenal — hemodynamically mediated reduction in glomerular perfusion from intravascular volume depletion — not intrinsic renal injury. The appropriate response is to reduce the furosemide dose (typically by 25–50%), not to discontinue empagliflozin. Empagliflozin's cardiovascular benefit in HFrEF is established and durable; removing it in response to a reversible volume-dependent creatinine rise sacrifices meaningful long-term protection to address a correctable hemodynamic problem. After loop diuretic dose reduction, the creatinine typically returns toward baseline as intravascular volume is restored. This scenario reinforces the clinical standard of proactively reducing the loop diuretic when initiating SGLT2 inhibitors in euvolemic patients.
Option A: Option B: Option B contains a true concept — modest initial eGFR decline with SGLT2 inhibitors is a hemodynamic class effect analogous to ACE inhibitors — but applying it here without any management change is incorrect given the magnitude of the creatinine rise (1.1 to 1.6, a 45% increase), the clinical signs of volume depletion, and the modifiable loop diuretic dose. A 45% creatinine rise with volume depletion signs requires intervention, not reassurance alone.
Option D: Option E:
Option A: Option A is incorrect — SGLT2 inhibitor-induced acute tubular necrosis at eGFR below 50 mL/min/1.73m² is not an established mechanism. The creatinine rise here is hemodynamically mediated (prerenal), evidenced by the volume depletion signs, not by tubular injury markers. Discontinuing empagliflozin and requesting nephrology consultation is disproportionate to a prerenal presentation with a clear reversible cause.
Option D: Option D fabricates a contrast nephropathy mechanism requiring empagliflozin discontinuation. No imaging study is mentioned, and contrast-SGLT2 inhibitor nephrotoxic synergy is not an established pharmacological interaction. The clinical presentation is entirely explained by additive diuretic volume depletion.
Option E: Option E is incorrect in recommending furosemide dose increase — this would worsen the existing volume depletion and drive the creatinine higher. While the eGFR of 44 mL/min/1.73m² may remain within the approved range for the heart failure indication, the clinical priority is to address the volume-depleted state causing the creatinine rise, not to add more diuresis.
2. A 58-year-old self-identified Black man with HFrEF (LVEF 31%, NYHA class III) has been on optimized therapy with sacubitril/valsartan 97/103 mg twice daily, carvedilol 25 mg twice daily, spironolactone 25 mg daily, and dapagliflozin 10 mg daily for 14 months. He remains symptomatic with dyspnea on minimal exertion and his NT-proBNP is persistently elevated at 2,800 pg/mL. His blood pressure is 118/72 mmHg and his resting heart rate is 68 bpm in sinus rhythm. Which of the following represents the most appropriate next therapeutic step?
A) Add hydralazine/isosorbide dinitrate (H/ISDN) — this patient meets the Class I guideline criteria for H/ISDN addition: he self-identifies as Black, has HFrEF, and remains symptomatic despite optimized four-pillar GDMT including ARNI, beta-blocker, MRA, and SGLT2 inhibitor; H/ISDN addresses the NO bioavailability deficit proposed to underlie differential benefit in this population
B) Add ivabradine 5 mg twice daily — the resting heart rate of 68 bpm does not meet the 70 bpm eligibility threshold, but the guideline permits a 5% variance below threshold in patients with persistent NYHA class III symptoms whose beta-blocker cannot be uptitrated further, making this patient eligible under the borderline heart rate exception
C) Add vericiguat 2.5 mg daily — this patient's persistent symptoms and elevated NT-proBNP despite four-pillar GDMT, combined with a recent worsening event, qualify him for vericiguat; the fact that he self-identifies as Black does not change the VICTORIA trial eligibility criteria, which enrolled patients regardless of race
D) Increase sacubitril/valsartan to the maximum dose of 200/300 mg twice daily before adding any new agent — current guidelines specify that ARNI must be at maximum tolerated dose before any fifth-pillar agent is considered, and this patient at 97/103 mg twice daily has not yet achieved the highest approved dose
E) Refer for cardiac resynchronization therapy (CRT) evaluation — the combination of NYHA class III symptoms, LVEF 31%, and persistent elevation of NT-proBNP despite optimized medical therapy meets the standard criteria for CRT consideration, and device therapy should be prioritized over further pharmacological addition at this stage
ANSWER: A
Rationale:
This patient meets both criteria for the Class I H/ISDN indication: he self-identifies as Black and has HFrEF with persistent symptoms despite optimized background GDMT. The ACC/AHA/HFSA 2022 guidelines give H/ISDN a Class I, Level of Evidence A recommendation specifically for self-identified Black patients with HFrEF who remain symptomatic on background neurohormonal therapy. The guideline explicitly includes patients on all four GDMT pillars — the four-pillar framework does not replace the H/ISDN indication for Black patients; rather, H/ISDN is added on top of optimized four-pillar therapy in this population. The biological rationale (impaired NO bioavailability, greater oxidative stress) supports the combination. His blood pressure of 118/72 mmHg is adequate to tolerate the vasodilatory effects of H/ISDN with appropriate monitoring. The heart rate of 68 bpm places him below the ivabradine threshold, and no recent worsening HF event is described, excluding vericiguat's primary indication.
Option B: Option C: Option D: Option E: Option E raises a valid clinical consideration — CRT evaluation is appropriate for HFrEF patients with NYHA class III and LVEF below 35% if QRS duration criteria are met — but the question asks for the most appropriate next pharmacological step, and CRT assessment is a device-based parallel consideration rather than a pharmacological choice. Additionally, CRT evaluation does not preclude simultaneous H/ISDN addition, and the question presents a pharmacological decision point.
Option B: Option B fabricates a "5% variance below threshold exception" for ivabradine in NYHA class III patients. No such guideline provision exists. The 70 bpm threshold is a firm eligibility criterion, and 68 bpm does not qualify regardless of symptom severity. Clinicians cannot apply ivabradine below the stated threshold based on symptom class.
Option C: Option C is incorrect because no recent worsening heart failure event is described in this patient's history. The VICTORIA trial and the vericiguat indication require a worsening HF event (hospitalization or outpatient IV diuresis) within the prior 6 months. Persistent symptoms and elevated NT-proBNP alone — without a qualifying worsening event — do not meet the vericiguat indication.
Option D: Option D incorrectly states that ARNI must be at maximum tolerated dose before any fifth-pillar agent is considered. Current guidelines do not specify a sequential optimization requirement of this kind — the simultaneous initiation approach applies, and there is no guideline mandate requiring ARNI uptitration as a prerequisite for H/ISDN addition. The patient is on a standard mid-range sacubitril/valsartan dose, and dose uptitration is a reasonable concurrent goal but not a prerequisite.
3. A 66-year-old woman with HFrEF and type 2 diabetes has been on empagliflozin 10 mg daily for 5 months. She is brought to the emergency department by her family after 2 days of nausea, vomiting, fatigue, and confusion. She has been eating very little for the past 4 days due to a gastrointestinal illness. Laboratory results: serum glucose 154 mg/dL, bicarbonate 9 mEq/L, anion gap 22 mEq/L (normal <12), urine ketones 4+, serum beta-hydroxybutyrate markedly elevated. Arterial blood gas: pH 7.18. Which of the following correctly identifies the diagnosis, the precipitating factor, and the immediate management priority?
A) This is hyperglycemic hyperosmolar state (HHS) — the glucose of 154 mg/dL, while only mildly elevated, represents the initial phase of HHS before osmolality becomes critically elevated; empagliflozin should be continued because it will lower the glucose and reduce osmolality, and aggressive IV fluid resuscitation with normal saline should be initiated at 1 L/hour
B) This is diabetic ketoacidosis (DKA) precipitated by the gastrointestinal illness in a patient with type 2 diabetes — empagliflozin is unrelated to the presentation because euglycemic DKA is exclusively a complication of type 1 diabetes or insulin-dependent type 2 diabetes; management is standard DKA protocol (insulin infusion, IV fluids, electrolyte replacement) without any change to empagliflozin
C) This is lactic acidosis from empagliflozin — SGLT2 inhibitors inhibit mitochondrial complex I in hepatocytes under conditions of reduced carbohydrate intake, accumulating NADH and shifting pyruvate toward lactate; immediate management requires bicarbonate infusion and empagliflozin discontinuation, with serum lactate measurement to confirm the diagnosis before initiating insulin
D) This is starvation ketoacidosis unrelated to empagliflozin — reduced carbohydrate intake for 4 days in a diabetic patient on a glucose-lowering agent predictably produces ketone accumulation; empagliflozin should be held until oral intake resumes but insulin infusion is unnecessary because the metabolic acidosis will resolve with IV glucose administration and refeeding alone
E) This is empagliflozin-associated euglycemic diabetic ketoacidosis (DKA) — precipitated by the combination of empagliflozin's glucosuria-driven shift toward ketogenesis and the physiological stress and carbohydrate restriction of the gastrointestinal illness; immediate management requires empagliflozin discontinuation, insulin infusion (to suppress ketogenesis even though glucose is near-normal), IV dextrose (to prevent hypoglycemia from insulin in the setting of near-normal glucose), and IV fluid and electrolyte replacement
ANSWER: E
Rationale:
This presentation is euglycemic diabetic ketoacidosis (DKA) associated with empagliflozin. The diagnostic triad is present: severe high anion gap metabolic acidosis (pH 7.18, bicarbonate 9, anion gap 22), marked ketonemia (4+ urine ketones, elevated beta-hydroxybutyrate), and only mild hyperglycemia (glucose 154 mg/dL) — the defining feature of euglycemic DKA is the absence of the profound hyperglycemia (typically above 250–300 mg/dL) expected in classic DKA. The precipitating mechanism involves two converging factors: (1) empagliflozin's pharmacological effects — SGLT2 inhibition promotes glucosuria, lowers insulin-to-glucagon ratio, and stimulates hepatic ketogenesis; (2) the physiological stress and near-complete carbohydrate restriction from the gastrointestinal illness, which further drives lipolysis, free fatty acid oxidation, and hepatic ketone production. The immediate management priorities are: discontinue empagliflozin; initiate insulin infusion to suppress ketogenesis — critically, this is necessary even though the glucose is near-normal, because the metabolic target is ketone suppression, not glucose lowering; administer IV dextrose simultaneously to prevent insulin-induced hypoglycemia; provide aggressive IV fluid and electrolyte replacement. The near-normal glucose level is the clinical trap — clinicians who delay insulin because "the glucose isn't high enough" allow the ketoacidosis to continue unchecked.
Option A: Option A misdiagnoses this as HHS, which is characterized by extreme hyperglycemia (typically above 600 mg/dL), profound dehydration, and minimal ketosis. The marked ketonemia (4+ urine ketones, elevated beta-hydroxybutyrate) and severe anion gap acidosis exclude HHS. Continuing empagliflozin in a patient with active DKA is dangerous and incorrect.
Option B: Option C: Option D: Option D minimizes the severity of the presentation and incorrectly proposes that IV glucose and refeeding alone will resolve a pH of 7.18 with anion gap 22. This degree of metabolic acidosis from ketoacidosis requires insulin to suppress ongoing ketone production; glucose-only refeeding is insufficient and dangerous at this pH.
Option B: Option B incorrectly restricts euglycemic DKA to type 1 diabetes or insulin-dependent type 2 diabetes. SGLT2 inhibitor-associated euglycemic DKA occurs in type 2 diabetic patients not requiring insulin and in non-diabetic patients on SGLT2 inhibitors for heart failure or CKD. The gastrointestinal illness and carbohydrate restriction are the precipitating stressors, not merely coincidental; empagliflozin is directly implicated.
Option C: Option C incorrectly identifies lactic acidosis and fabricates a complex I inhibition mechanism for empagliflozin. Lactic acidosis produces elevated lactate without significant ketonemia; this patient's 4+ urine ketones and elevated beta-hydroxybutyrate confirm a ketoacidotic rather than lactic process. Empagliflozin does not inhibit hepatic mitochondrial complex I.
4. A 63-year-old man with HFrEF (LVEF 29%) on maximally tolerated bisoprolol 10 mg daily was started on ivabradine 7.5 mg twice daily 8 weeks ago because his resting heart rate was 78 bpm. At today's visit he is asymptomatic but his resting heart rate is 42 bpm. His blood pressure is 112/68 mmHg, he has no signs of low cardiac output, and he reports no dizziness or presyncope. Which of the following correctly describes the appropriate management of his symptomatic bradycardia, and the sequence in which ivabradine and bisoprolol adjustments should be made?
A) Discontinue bisoprolol immediately and reduce ivabradine to 5 mg twice daily — bisoprolol contributes more to the resting heart rate reduction in HFrEF than ivabradine at equivalent clinical doses, and removing it first while maintaining partial ivabradine coverage preserves the cardiac benefit of rate reduction while eliminating the more potent bradycardic agent
B) Reduce ivabradine to 5 mg twice daily as the immediate first step — if the heart rate normalizes to above 50 bpm on the reduced ivabradine dose, reassess at 2 weeks; if bradycardia persists or the patient becomes symptomatic, consider further ivabradine dose reduction or discontinuation before touching the bisoprolol dose, as beta-blocker continuity is a mortality-reducing priority in HFrEF
C) Discontinue both bisoprolol and ivabradine simultaneously — the combination has produced a degree of heart rate suppression incompatible with adequate cardiac output in HFrEF; both agents must be cleared before any re-initiation strategy is planned with lower doses of each
D) Discontinue ivabradine completely and reduce bisoprolol to 5 mg daily — ivabradine has no mortality benefit in HFrEF independent of heart rate reduction and can be eliminated without long-term consequence, while bisoprolol's neurohormonal blockade must be preserved at the highest tolerated dose; reducing bisoprolol by 50% while eliminating ivabradine achieves the required heart rate increase with minimal loss of neurohormonal protection
E) Continue both agents unchanged and repeat the heart rate measurement in 4 weeks — a resting heart rate of 42 bpm in an asymptomatic patient with normal blood pressure and no low-output signs does not meet the threshold for pharmacological intervention; the SHIFT trial demonstrated that lower heart rates produce greater event reduction and the current rate, while below standard targets, represents optimal pharmacological effect
ANSWER: B
Rationale:
The management of ivabradine-associated bradycardia follows a clear priority principle: preserve beta-blocker therapy because it has established mortality benefit in HFrEF independent of heart rate reduction, and adjust ivabradine first because its sole mechanism of benefit is heart rate reduction — a benefit that becomes zero or negative when the rate is excessively suppressed. The first step is to reduce ivabradine from 7.5 mg to 5 mg twice daily (the lower approved dose), reassess the heart rate response over 2 weeks, and only consider bisoprolol dose reduction if bradycardia persists despite ivabradine dose reduction. A resting heart rate of 42 bpm, even in an asymptomatic patient, carries risk of symptomatic bradycardia with minimal exertion and represents over-suppression of the sinoatrial node that requires correction. The ivabradine dose reduction is the pharmacologically appropriate first step precisely because ivabradine's cardiovascular benefit is entirely mediated by heart rate reduction — at 42 bpm, the benefit-risk ratio of continued full-dose ivabradine is unfavorable. If dose reduction to 5 mg twice daily still leaves the rate below 50 bpm, ivabradine should be discontinued entirely before any bisoprolol adjustment is considered.
Option A: Option A proposes discontinuing bisoprolol first — the reverse of the correct priority. Bisoprolol provides neurohormonal blockade (mortality benefit) independent of its heart rate-lowering effect; removing it to manage bradycardia sacrifices that benefit unnecessarily when ivabradine dose reduction is the pharmacologically logical first step.
Option C: Option C proposes simultaneous discontinuation of both agents — an overly aggressive response to asymptomatic bradycardia in a hemodynamically stable patient. Abrupt beta-blocker discontinuation in HFrEF risks rebound sympathetic activation, which can precipitate acute decompensation or arrhythmia. Discontinuing both agents simultaneously is not the appropriate approach.
Option D: Option D proposes complete ivabradine discontinuation and 50% bisoprolol dose reduction simultaneously. While eventually ivabradine discontinuation may be appropriate if dose reduction is insufficient, reducing bisoprolol simultaneously in the first step is not indicated when the primary over-contribution to bradycardia is from the ivabradine dose. Preserving full bisoprolol dose during the initial management step is the priority.
Option E:
Option E: Option E is incorrect — a resting heart rate of 42 bpm requires intervention. While the patient is currently asymptomatic at rest, a heart rate of 42 bpm leaves minimal reserve for any increase in activity, and SHIFT demonstrated benefit from rate reduction only when the rate was above the 70 bpm threshold before treatment; the trial did not endorse rates of 42 bpm as a therapeutic target. Watchful waiting without dose adjustment is inappropriate at this degree of suppression.
5. A 70-year-old man with HFrEF (LVEF 26%, NYHA class III) was hospitalized 3 weeks ago for worsening heart failure requiring 4 days of intravenous furosemide. He is now euvolemic on his baseline oral regimen: sacubitril/valsartan 97/103 mg twice daily, carvedilol 12.5 mg twice daily, eplerenone 25 mg daily, and dapagliflozin 10 mg daily. His NT-proBNP at discharge was 5,200 pg/mL and today remains 4,800 pg/mL. His blood pressure is 106/64 mmHg and his resting heart rate is 72 bpm in sinus rhythm. His cardiologist decides to initiate vericiguat. Which of the following correctly describes the approved starting dose, uptitration schedule, and a relevant hemodynamic consideration for this patient?
A) Vericiguat is initiated at 10 mg daily — the starting and maintenance dose established in VICTORIA — and no uptitration is required; the fixed-dose approach simplifies initiation in high-risk patients already on complex regimens, and the blood pressure of 106/64 mmHg is within the approved range for initiation as long as the patient is monitored weekly for the first month
B) Vericiguat is initiated at 5 mg daily for 2 weeks, then increased to 10 mg daily if tolerated — the initial lower dose allows hemodynamic assessment before reaching the target dose; a blood pressure of 106/64 mmHg is borderline for vericiguat initiation and the cardiologist should consider holding the morning sacubitril/valsartan dose on the day of vericiguat initiation to reduce the risk of additive hypotension
C) Vericiguat is initiated at 1.25 mg daily for 2 weeks, then uptitrated at 2-week intervals through 2.5 mg, 5 mg, and finally 10 mg daily as tolerated — the 4-step uptitration is required because vericiguat's vasodilatory effect compounds rapidly with each dose doubling; the blood pressure of 106/64 mmHg is a relative contraindication requiring cardiology attending sign-off before each dose escalation step
D) Vericiguat is initiated at 2.5 mg once daily with food and uptitrated at approximately 2-week intervals to 5 mg once daily, then to the target dose of 10 mg once daily, as tolerated based on blood pressure and symptoms — the blood pressure of 106/64 mmHg is on the lower end and warrants careful monitoring during uptitration, particularly given the concurrent vasodilatory effects of sacubitril/valsartan and dapagliflozin
E) Vericiguat is initiated at 2.5 mg twice daily (to divide the vasodilatory load across two daily doses), uptitrated to 5 mg twice daily after 4 weeks if tolerated, with the blood pressure of 106/64 mmHg representing a caution but not a contraindication — the twice-daily schedule reduces peak plasma concentration and thereby reduces peak vasodilation, making it the preferred initiation strategy in patients with borderline blood pressure
ANSWER: D
Rationale:
Vericiguat is initiated at 2.5 mg once daily (taken with food — food increases bioavailability and reduces peak-to-trough plasma concentration variability) and uptitrated at approximately 2-week intervals: 2.5 mg → 5 mg → 10 mg once daily, as tolerated. This 3-step uptitration reaching a target of 10 mg daily was the dosing protocol used in the VICTORIA trial and is the approach specified in the FDA-approved prescribing information. The rationale for gradual uptitration is vericiguat's vasodilatory mechanism: each dose increase produces further cGMP-mediated vasodilation (both arterial and venous), and in patients with already low-normal blood pressure — as in this patient at 106/64 mmHg — each uptitration step carries a risk of symptomatic hypotension. The concurrent medications compound this concern: sacubitril/valsartan produces RAAS-mediated vasodilation and natriuresis, and dapagliflozin produces volume reduction — together with vericiguat's vasodilation, the hemodynamic interaction requires careful monitoring. Taking vericiguat with food and monitoring blood pressure at each uptitration visit are standard clinical practice points.
Option A: Option B: Option C: Option E:
Option A: Option A is incorrect — vericiguat is not initiated at the 10 mg target dose. A titration schedule starting at 2.5 mg is required to allow hemodynamic tolerance assessment before reaching the target dose. Initiating at 10 mg risks acute symptomatic hypotension, particularly in this patient with borderline blood pressure.
Option B: Option B describes a 2-step titration (5 mg → 10 mg) that skips the 2.5 mg starting dose specified in the prescribing information. The recommendation to hold sacubitril/valsartan on initiation day is also not a standard clinical practice instruction and could disrupt the patient's established neurohormonal regimen unnecessarily.
Option C: Option C describes a 4-step titration starting at 1.25 mg, which is not the approved starting dose. The approved initiation dose is 2.5 mg once daily. A 1.25 mg starting dose is not specified in prescribing information, and the description of a relative contraindication requiring attending sign-off at each step is not an established regulatory or guideline requirement.
Option E: Option E is incorrect — vericiguat is approved as a once-daily medication, not twice daily. The rationale for twice-daily dosing to reduce peak vasodilation is pharmacologically plausible in concept but is not the approved regimen. Administering a once-daily drug in divided doses alters the pharmacokinetic profile in ways not supported by the trial data.
6. A cardiologist is reviewing four patients with HFrEF for dapagliflozin initiation. Which of the following patient profiles most clearly represents a situation requiring special caution or representing a relative contraindication, requiring explicit risk-benefit discussion before SGLT2 inhibitor initiation?
A) A 61-year-old man with HFrEF, eGFR 58 mL/min/1.73m², and type 1 diabetes managed with an insulin pump — he has had two prior episodes of diabetic ketoacidosis in the past 4 years, the most recent occurring during a febrile illness; SGLT2 inhibitors carry substantially elevated DKA risk in type 1 diabetes, and prior DKA episodes in the context of physiological stress further amplify this risk, making initiation a decision requiring explicit risk-benefit counseling and a clear sick-day management plan
B) A 74-year-old woman with HFrEF, eGFR 44 mL/min/1.73m², no diabetes, and a history of one uncomplicated urinary tract infection 2 years ago treated with a 3-day course of trimethoprim-sulfamethoxazole — her eGFR is within the currently approved threshold for dapagliflozin in heart failure, and a single prior UTI is not a contraindication; initiation is appropriate with standard counseling
C) A 67-year-old man with HFrEF, eGFR 62 mL/min/1.73m², type 2 diabetes managed with metformin and sitagliptin, and a body mass index of 34 kg/m² — his eGFR is adequate, type 2 diabetes is not a contraindication, and obesity is associated with greater hemodynamic benefit from SGLT2-mediated volume reduction; initiation is appropriate and may provide additional metabolic benefits
D) A 69-year-old woman with HFrEF, eGFR 51 mL/min/1.73m², no diabetes, and a history of a single episode of Candida vulvovaginitis 18 months ago that resolved with a single dose of fluconazole — her renal function is adequate and a single prior genital mycotic infection is a caution but not a contraindication; initiation with counseling about recurrence risk and antifungal availability is appropriate
E) A 71-year-old man with HFrEF, eGFR 66 mL/min/1.73m², no diabetes, and stable GDMT including sacubitril/valsartan, metoprolol succinate, spironolactone — his eGFR is adequate, no diabetes or prior SGLT2-related adverse events are present, and his existing regimen does not contraindicate dapagliflozin; initiation is appropriate and this patient profile is the intended target of the DAPA-HF non-diabetic subgroup
ANSWER: A
Rationale:
Type 1 diabetes represents a relative contraindication to SGLT2 inhibitor use primarily because of a substantially elevated risk of euglycemic DKA. In type 1 diabetes, the absolute insulin deficiency produces a baseline glucagon-to-insulin ratio that is already tilted toward ketogenesis; SGLT2 inhibitor-mediated glucosuria further shifts this ratio, dramatically lowering the threshold at which ketoacidosis can occur. This risk is compounded in a patient with prior DKA episodes — particularly when prior events were precipitated by physiological stressors (febrile illness) analogous to the situations that most commonly precipitate SGLT2 inhibitor-associated DKA (surgery, fasting, illness). SGLT2 inhibitors are not FDA-approved for type 1 diabetes in the United States for this reason, and use in type 1 diabetic patients with HFrEF is off-label and requires explicit discussion of the elevated DKA risk, a clear sick-day management plan (hold SGLT2 inhibitor at onset of illness, febrile episode, or reduced intake), and close monitoring. This is the most clearly defined special-caution scenario among the options presented.
Option B: Option B correctly identifies a patient who is appropriate for initiation — eGFR 44 mL/min/1.73m² is above the currently approved lower threshold for dapagliflozin in the heart failure indication (approximately eGFR ≥25 mL/min/1.73m² for HFrEF), and a single prior uncomplicated UTI is not a contraindication. This patient can receive dapagliflozin with standard counseling.
Option C: Option C correctly identifies a patient appropriate for initiation — type 2 diabetes with metformin and a DPP-4 inhibitor (sitagliptin) does not contraindicate SGLT2 inhibitor use; SGLT2 inhibitors and DPP-4 inhibitors are commonly used together in type 2 diabetes management, and the combination carries no additive risk of significant hypoglycemia. Obesity and adequate eGFR support initiation.
Option D: Option D correctly identifies a patient appropriate for initiation — a single prior Candida vulvovaginitis episode that resolved fully with one dose of fluconazole is a recognized caution but not a contraindication. The patient should be counseled about recurrence risk and advised to have fluconazole available, but initiation is appropriate.
Option E: Option E correctly identifies a patient appropriate for initiation — adequate renal function, no diabetes, no prior SGLT2-related adverse events, and a background regimen without contraindications. This patient represents the non-diabetic HFrEF population in whom benefit was established in DAPA-HF.
7. A clinician is considering H/ISDN for a patient with HFrEF who cannot tolerate RAAS blockade. Which of the following clinical scenarios correctly represents a qualifying intolerance for the second Class I H/ISDN indication (RAAS-intolerant patients), versus a scenario that does not qualify?
A) Qualifying: a patient who developed angioedema on lisinopril and subsequently on valsartan, representing true bradykinin-pathway intolerance to both ACE inhibitors and ARBs. Non-qualifying: a patient who discontinued lisinopril due to a dry cough and was never trialed on an ARB or ARNI — cough alone on an ACE inhibitor does not establish RAAS class intolerance, since cough is an ACE inhibitor-specific effect mediated by bradykinin accumulation that does not occur with ARBs or ARNIs; this patient should be switched to valsartan or sacubitril/valsartan rather than H/ISDN
B) Qualifying: a patient who developed hyperkalemia (serum potassium 5.8 mEq/L) on lisinopril 5 mg daily that resolved after discontinuation. Non-qualifying: a patient who developed worsening creatinine on both lisinopril and valsartan that was managed with dose reduction but not discontinuation — neither scenario represents the definitive class intolerance required for the H/ISDN indication, and both patients should have their RAAS agents dose-adjusted before H/ISDN is considered
C) Qualifying: a patient who developed angioedema on enalapril and subsequently on sacubitril/valsartan (which contains valsartan, an ARB, and sacubitril, a neprilysin inhibitor that elevates bradykinin), confirming true bradykinin-pathway intolerance to the entire RAAS blockade/ARNI class. Non-qualifying: a patient who developed a dry cough on ramipril — ACE inhibitor-induced cough is a bradykinin-mediated class effect specific to ACE inhibitors; switching to an ARB or ARNI is the appropriate next step, as these agents do not elevate bradykinin to the same degree
D) Qualifying: a patient who developed severe hypotension (systolic BP 78 mmHg) on the first dose of captopril requiring emergency room visit, who was never rechallenged with any RAAS agent. Non-qualifying: a patient who developed angioedema on lisinopril and was subsequently managed with sacubitril/valsartan without recurrence of angioedema — since sacubitril/valsartan was tolerated, the patient does not have true RAAS class intolerance and H/ISDN is not the appropriate next step
E) Qualifying: a patient who developed bilateral leg edema and a 3 kg weight gain on spironolactone that resolved after discontinuation — this confirms MRA intolerance, which the guidelines treat as equivalent to RAAS intolerance for the H/ISDN indication. Non-qualifying: a patient who developed a serum potassium of 5.4 mEq/L on eplerenone that resolved with dietary potassium restriction — mild hyperkalemia managed without discontinuation does not constitute RAAS intolerance
ANSWER: C
Rationale:
This question requires distinguishing which intolerance patterns constitute true RAAS blockade class intolerance justifying H/ISDN substitution versus adverse effects that can be addressed within the RAAS class. Option C correctly pairs two scenarios: the qualifying case — angioedema on an ACE inhibitor followed by angioedema on sacubitril/valsartan (which contains valsartan plus sacubitril, a neprilysin inhibitor that elevates bradykinin levels and would be expected to worsen bradykinin-mediated angioedema) — confirms intolerance to the entire RAAS/ARNI class. Angioedema is the definitive contraindication to further RAAS-based therapy, and sacubitril/valsartan is specifically contraindicated in patients with prior ACE inhibitor angioedema. This patient has no remaining RAAS option, making H/ISDN the appropriate Class I alternative. The non-qualifying case — cough on an ACE inhibitor — is correctly identified as an ACE inhibitor-specific bradykinin effect; the appropriate management is switching to an ARB (which does not elevate bradykinin) or ARNI, not declaring RAAS class intolerance and moving to H/ISDN.
Option A: Option A also correctly identifies cough as a non-qualifying intolerance and angioedema on both ACE inhibitor and ARB as qualifying. However, it incompletely addresses sacubitril/valsartan — in the qualifying scenario described in A, the patient who had angioedema on valsartan might also tolerate sacubitril/valsartan if the ARB angioedema was idiosyncratic rather than class-mediated. Option C is more clinically complete by including sacubitril/valsartan failure in the qualifying scenario, confirming exhaustion of the entire RAAS/ARNI class.
Option B: Option D: Option E:
Option B: Option B is incorrect in classifying both hyperkalemia and creatinine elevation as non-qualifying — significant hyperkalemia requiring discontinuation (not merely dose reduction) and renal insufficiency requiring permanent RAAS discontinuation can constitute class intolerance, particularly if the patient cannot tolerate any RAAS agent at any dose. The blanket statement that both patients need dose adjustment before H/ISDN is considered is overly simplistic.
Option D: Option D incorrectly classifies first-dose hypotension on captopril as a qualifying intolerance. First-dose hypotension is typically a hemodynamic response to volume depletion or excessive starting dose — it does not represent class intolerance if not rechallenged. More importantly,
Option D: Option D incorrectly states that tolerance of sacubitril/valsartan after ACE inhibitor angioedema means the patient lacks RAAS class intolerance. In fact, sacubitril/valsartan is contraindicated in patients with ACE inhibitor angioedema because neprilysin inhibition further elevates bradykinin; if a patient with ACE inhibitor angioedema is managed with sacubitril/valsartan and tolerates it, that would be a concerning clinical decision rather than evidence of non-intolerance.
Option E: Option E incorrectly classifies MRA intolerance (spironolactone) as equivalent to RAAS intolerance for the H/ISDN indication. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) are a separate GDMT pillar — their intolerance does not constitute the RAAS blockade (ACE inhibitor/ARB/ARNI) intolerance that triggers the H/ISDN Class I indication.
8. A 67-year-old woman with HFrEF (LVEF 33%, NYHA class II) has been on ivabradine 7.5 mg twice daily for 6 months, added to maximally tolerated metoprolol succinate 100 mg daily because her resting heart rate was 76 bpm. She was doing well until 10 days ago when she noted the onset of palpitations and irregular heartbeat. An ECG confirms new-onset atrial fibrillation with a ventricular rate of 92 bpm. She is hemodynamically stable. Her other medications are sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, and dapagliflozin 10 mg daily. Which of the following correctly identifies the complete immediate management plan for this patient?
A) Continue ivabradine and increase metoprolol succinate to 150 mg daily to achieve rate control in atrial fibrillation — ivabradine's HCN channel blockade complements metoprolol's AV nodal slowing and together they will reduce the ventricular rate more effectively than either agent alone; the ivabradine dose should be maintained at 7.5 mg twice daily to preserve the rate-reduction benefit established before the AF onset
B) Discontinue ivabradine and optimize metoprolol succinate for rate control in atrial fibrillation — ivabradine has no mechanism for slowing ventricular rate in AF (it acts on the sinoatrial node, which is not driving the ventricular rate in AF), so continuing it provides no clinical benefit while maintaining adverse effect exposure; rate control should rely on metoprolol, with consideration of digoxin if the ventricular rate remains inadequately controlled; additionally evaluate for anticoagulation indication given new AF and HFrEF
C) Discontinue metoprolol succinate and continue ivabradine at the current dose — metoprolol's AV nodal slowing is more potent than its sinoatrial node effect and may paradoxically worsen AF by slowing AV nodal conduction without restoring sinus rhythm; ivabradine maintains sinoatrial node readiness for spontaneous cardioversion and provides rate-independent cardioprotection through its anti-remodeling properties
D) Hold both ivabradine and metoprolol succinate for 48 hours and repeat the ECG — transient AF in HFrEF is frequently self-terminating within 48 hours, and withholding both rate-control agents allows the sinus node to recover its dominant pacemaker function spontaneously; reinitiate both agents at half dose once sinus rhythm is confirmed
E) Discontinue ivabradine and add digoxin 0.125 mg daily as the sole rate-control agent — metoprolol succinate should also be discontinued because beta-blockade in AF with HFrEF reduces cardiac output excessively; digoxin alone controls ventricular rate through AV nodal slowing without negative inotropy, making it the preferred agent in this setting
ANSWER: B
Rationale:
This question requires applying two simultaneous clinical decisions: (1) what to do with ivabradine in new-onset AF, and (2) how to manage rate control and broader AF management in HFrEF. On ivabradine: the drug must be discontinued because its mechanism of action — HCN4 channel blockade in the sinoatrial node — has no pharmacological effect on ventricular rate in AF. In AF, the ventricular rate is determined by AV nodal conduction, not by sinoatrial node firing. Continuing ivabradine in AF exposes the patient to adverse effects (phosphenes, potential bradycardia if sinus rhythm spontaneously restores) without any benefit. On rate control: metoprolol succinate is a first-line rate control agent in AF and should be optimized (up-titrated toward 200 mg daily as tolerated) now that ivabradine has been removed. If the ventricular rate remains above 80 bpm at rest despite optimized metoprolol, addition of digoxin is a reasonable second-line option in HFrEF patients — digoxin slows ventricular rate through AV nodal mechanisms without negative inotropy. On anticoagulation: new-onset AF in a patient with HFrEF warrants CHA₂DS₂-VASc score calculation and anticoagulation consideration — this is an important management component that Option B correctly identifies.
Option A: Option C: Option D: Option E:
Option A: Option A is incorrect — ivabradine does not complement metoprolol's AV nodal slowing in AF. They act through entirely different mechanisms: metoprolol slows AV nodal conduction (relevant in AF); ivabradine slows sinoatrial node spontaneous depolarization (irrelevant in AF). Continuing ivabradine at 7.5 mg twice daily in AF provides no rate control benefit.
Option C: Option C is incorrect on multiple counts — metoprolol succinate should not be discontinued in AF with HFrEF; it is a first-line rate control agent. The claim that metoprolol "paradoxically worsens AF" by slowing AV conduction is incorrect — slowing AV nodal conduction is precisely the desired mechanism for ventricular rate control in AF. Ivabradine has no established anti-remodeling properties that would justify continuing it once its rate-control mechanism is pharmacologically inoperative.
Option D: Option D is incorrect — withholding both rate-control agents for 48 hours in a patient with AF at 92 bpm and HFrEF risks hemodynamic deterioration from sustained tachycardia. Spontaneous AF termination is not reliably predictable, and passive observation while holding both agents is not appropriate management. Metoprolol should be continued and optimized, not withheld.
Option E: Option E is incorrect — metoprolol succinate should not be discontinued in HFrEF with AF. The claim that beta-blockade reduces cardiac output excessively in AF with HFrEF is overstated; beta-blockers are first-line rate control agents in this setting and provide neurohormonal mortality benefit that must be preserved. Digoxin alone is not the preferred sole rate-control agent; it is used as an adjunct when beta-blocker alone is insufficient.
9. A 64-year-old man with HFrEF (LVEF 28%) and concurrent pulmonary arterial hypertension (PAH — elevated pressure in the pulmonary vasculature due to increased pulmonary vascular resistance, distinct from pulmonary hypertension caused by left heart failure) has been stable on vericiguat 10 mg daily for 5 months as part of his HFrEF regimen. His pulmonologist initiates sildenafil (a PDE5 inhibitor — a drug that prevents breakdown of cGMP in vascular smooth muscle) for his PAH. Two weeks later he presents to the emergency department with severe symptomatic hypotension: blood pressure 74/42 mmHg, heart rate 118 bpm, and lightheadedness. Which of the following correctly identifies the mechanism of this interaction and the immediate management priority?
A) The hypotension results from sildenafil inhibiting CYP3A4, which metabolizes vericiguat — the resulting vericiguat accumulation produces excessive sGC stimulation and cGMP elevation in vascular smooth muscle, causing severe vasodilation; the immediate management is activated charcoal to limit further vericiguat absorption and IV phenylephrine to restore vascular tone
B) The hypotension results from a pharmacodynamic interaction: sildenafil prevents the breakdown of cGMP (by inhibiting PDE5 — the phosphodiesterase enzyme that degrades cGMP in vascular smooth muscle), while vericiguat simultaneously stimulates more cGMP production (by activating sGC); the combination produces additive or synergistic cGMP elevation in vascular smooth muscle, causing severe vasodilation through the same mechanism that makes sildenafil-nitrate co-administration dangerous; immediate management is aggressive IV fluid resuscitation, vasopressor support (norepinephrine) as needed, and discontinuation of both agents pending stabilization
C) The hypotension results from vericiguat displacing sildenafil from plasma protein binding sites, dramatically increasing free (unbound) sildenafil concentration and producing an acute pharmacokinetic interaction — the combination does not represent a class-level contraindication, and the appropriate management is dose reduction of sildenafil to 12.5 mg three times daily with vericiguat continuation at the current dose
D) The hypotension results from sildenafil's PDE5 inhibition in cardiac myocytes reducing contractility in the failing ventricle — sildenafil is absolutely contraindicated in HFrEF because cGMP elevation in cardiomyocytes suppresses the Frank-Starling mechanism; immediate management is IV dobutamine to restore contractility and sildenafil must be permanently discontinued with a formal FDA MedWatch report filed
E) The hypotension results from the additive cGMP pathway vasodilation: vericiguat drives more cGMP production through sGC stimulation while sildenafil prevents its degradation through PDE5 inhibition — together they create a state of unregulated cGMP excess in vascular smooth muscle producing severe hypotension; this interaction is pharmacologically analogous to the sildenafil-nitrate interaction (both involve cGMP excess by different mechanisms) and was a recognized safety concern that contraindicated co-administration of vericiguat with PDE5 inhibitors; immediate management includes IV fluids, vasopressor support as needed, and discontinuation of both agents
ANSWER: E
Rationale:
This case illustrates a pharmacodynamically predictable and serious drug interaction between vericiguat and sildenafil. The mechanism has two complementary components acting on the same cGMP pathway: vericiguat stimulates soluble guanylate cyclase (sGC) to produce more cGMP from GTP, while sildenafil inhibits phosphodiesterase-5 (PDE5) to prevent cGMP degradation. The net result is markedly elevated intracellular cGMP in vascular smooth muscle cells — producing vasodilation through activation of cGMP-dependent protein kinase G (PKG), which relaxes myosin light chain kinase and causes vascular smooth muscle relaxation. This is the same pathway excess that makes sildenafil co-administration with organic nitrates dangerous (nitrates increase cGMP via NO-sGC activation; sildenafil prevents its breakdown — causing severe hypotension). Vericiguat-PDE5 inhibitor co-administration was contraindicated in the VICTORIA trial and is listed as a contraindication in vericiguat's prescribing information precisely for this reason. Immediate management priorities are hemodynamic stabilization: aggressive IV fluid resuscitation to increase preload, vasopressor support (norepinephrine is the preferred agent to restore vascular tone through alpha-1 receptor activation) if hypotension persists despite fluids, and discontinuation of both agents. Option B and Option E both correctly identify the mechanism; Option E is the more complete and precise answer in explicitly naming the contraindication status and the pharmacological analogy to the sildenafil-nitrate interaction.
Option A: Option B: Option B correctly identifies the pharmacodynamic mechanism and the management priorities. However, it does not explicitly name the contraindication status of the combination or make the analogy to the sildenafil-nitrate interaction — making Option E the more complete answer for a Tier 3 question requiring full clinical and pharmacological integration.
Option C: Option D:
Option A: Option A fabricates a pharmacokinetic interaction through CYP3A4 inhibition by sildenafil causing vericiguat accumulation. While sildenafil has some CYP3A4 inhibitory activity, this is not the primary mechanism of the interaction. The interaction is pharmacodynamic (additive cGMP pathway activation), not pharmacokinetic. Activated charcoal is not the appropriate acute management for established hypotension.
Option C: Option C fabricates a protein binding displacement interaction and incorrectly characterizes this as a non-class-level interaction requiring dose reduction rather than discontinuation. Protein displacement interactions are rarely clinically significant, and the vericiguat-PDE5 inhibitor interaction is a pharmacodynamic contraindication, not a pharmacokinetic dose-adjustment scenario.
Option D: Option D fabricates negative inotropy from sildenafil in cardiac myocytes as the mechanism of hypotension. Sildenafil's hypotensive effect in this context is vascular (vasodilation from cGMP excess in smooth muscle), not from reduced myocardial contractility. IV dobutamine is not indicated for vasodilatory hypotension. The absolute contraindication framing and FDA MedWatch requirement as an immediate management step are not the primary management priorities in acute hemodynamic compromise.
10. A cardiologist is reviewing the heart failure literature and asks which patient profile within the HFpEF spectrum (ejection fraction above 40%) has the most robust trial evidence supporting SGLT2 inhibitor benefit, based on the EMPEROR-Preserved and DELIVER trial data. Which of the following correctly identifies the patient profile with the strongest evidence base?
A) Patients with HFpEF and concurrent type 2 diabetes exclusively — both EMPEROR-Preserved and DELIVER showed statistically significant primary endpoint reductions only in the diabetic subgroups, with the non-diabetic HFpEF subgroups showing non-significant trends; the overall significant result reflects the diabetic majority enrollment in both trials
B) Patients with HFmrEF (mildly reduced ejection fraction — LVEF 40–49%) specifically — subgroup analyses from both EMPEROR-Preserved and DELIVER showed larger hazard ratios and greater absolute risk reduction in the HFmrEF subgroup compared to the HFpEF (LVEF ≥50%) subgroup, suggesting that the preserved ejection fraction indication is driven primarily by the mildly reduced subgroup
C) Patients with HFpEF and a recent worsening heart failure event (hospitalization or outpatient IV diuresis within 6 months) — both trials enriched for this subgroup by requiring elevated NT-proBNP as an enrollment criterion, and post-hoc analyses show that the benefit was concentrated in patients with recent worsening, making this the highest-evidence subgroup analogous to the VICTORIA vericiguat indication
D) Patients across the full ejection fraction range above 40% — including both HFmrEF (LVEF 40–49%) and HFpEF (LVEF ≥50%) — regardless of diabetes status; both EMPEROR-Preserved and DELIVER demonstrated statistically significant reductions in the primary composite endpoint across this range, with consistent benefit in diabetic and non-diabetic patients and across HFmrEF and HFpEF subgroups, establishing the broadest evidence base for SGLT2 inhibitor use in preserved and mildly reduced ejection fraction
E) Patients with HFpEF and concurrent chronic kidney disease (eGFR below 60 mL/min/1.73m²) — the renoprotective mechanism of SGLT2 inhibitors synergizes with the cardiovascular benefit in this subgroup, producing the largest absolute risk reductions and the only statistically significant results in pre-specified subgroup analyses; patients with normal renal function and HFpEF show non-significant trends only
ANSWER: D
Rationale:
The evidence base for SGLT2 inhibitors in HFpEF and HFmrEF rests on two large randomized trials — EMPEROR-Preserved (empagliflozin, LVEF above 40%) and DELIVER (dapagliflozin, LVEF above 40%) — both of which demonstrated statistically significant reductions in their primary composite endpoints in the overall enrolled population. Subgroup analyses in both trials showed consistent benefit across the ejection fraction range (both HFmrEF and HFpEF subgroups) and across diabetes status (both diabetic and non-diabetic patients). No single subgroup — diabetic, HFmrEF, recent worsening event, or CKD — can be identified as the sole driver of the positive overall result; the benefit was broadly consistent. A pooled meta-analysis of EMPEROR-Preserved and DELIVER (the EMPACT-HF and related analyses) further supported consistent benefit across the full ejection fraction range above 40%. The current ACC/AHA/HFSA 2022 guideline recommendation reflects this breadth: SGLT2 inhibitors are recommended for HF patients across the ejection fraction spectrum, including HFpEF and HFmrEF, regardless of diabetes status. Option D most accurately represents the actual trial evidence base.
Option A: Option B: Option C: Option E:
Option A: Option A is incorrect — both EMPEROR-Preserved and DELIVER showed significant primary endpoint reductions in the overall population including non-diabetic patients. The non-diabetic subgroups were pre-specified, adequately powered, and showed consistent benefit. Restricting the evidence to diabetic patients misrepresents the trial findings and contradicts the basis for the diabetes-independent guideline recommendation.
Option B: Option B is incorrect — while HFmrEF patients may have shown numerically larger hazard ratios in some subgroup analyses, this does not mean the preserved ejection fraction indication is driven primarily by HFmrEF. Both EMPEROR-Preserved (which enrolled primarily LVEF above 50% patients) and DELIVER demonstrated benefit across the full above-40% EF spectrum, and no pre-specified analysis restricted the significant benefit to HFmrEF only.
Option C: Option C is incorrect — neither EMPEROR-Preserved nor DELIVER required a recent worsening HF event as an enrollment criterion (unlike VICTORIA for vericiguat). Both trials enrolled stable patients with elevated NT-proBNP as a risk marker, not as a surrogate for recent worsening. Post-hoc analyses showing benefit concentrated in recent-worsening subgroups do not constitute the primary evidence base and would not appropriately restrict the indication.
Option E: Option E is incorrect — the benefit in EMPEROR-Preserved and DELIVER was not restricted to patients with concurrent CKD. Both trials enrolled patients across a range of renal function, and subgroup analyses confirmed consistent benefit regardless of baseline eGFR. Restricting the evidence base to the CKD subgroup misrepresents the breadth of the positive trial results.
11. A 69-year-old self-identified Black woman with HFrEF (LVEF 30%, NYHA class III) is on sacubitril/valsartan 97/103 mg twice daily, carvedilol 25 mg twice daily, spironolactone 25 mg daily, and dapagliflozin 10 mg daily. She was hospitalized 2 months ago for worsening heart failure. Her current resting heart rate is 74 bpm in sinus rhythm, NT-proBNP is 3,600 pg/mL, and blood pressure is 116/70 mmHg. She is also on isosorbide mononitrate 30 mg daily for stable angina. Her cardiologist is considering adding H/ISDN, vericiguat, or ivabradine. Which of the following correctly identifies the most appropriate next pharmacological step, accounting for all eligibility criteria, drug interactions, and clinical priorities?
A) Add H/ISDN after discontinuing the isosorbide mononitrate — this patient meets the Class I criteria for H/ISDN addition (self-identified Black, HFrEF, symptomatic on optimized four-pillar GDMT), and this is the highest-priority pharmacological addition; however, the isosorbide mononitrate must be discontinued or substituted with a non-nitrate antianginal before H/ISDN can be initiated, since both isosorbide mononitrate and isosorbide dinitrate (the nitrate component of H/ISDN) act through the same NO-cGMP pathway and concomitant use represents additive nitrate exposure rather than a contraindicated pharmacodynamic interaction — the clinician should address the angina management with a non-nitrate strategy (such as ranolazine or optimization of the carvedilol dose for angina) before initiating H/ISDN
B) Add vericiguat 2.5 mg daily — this patient qualifies on the basis of recent worsening hospitalization and persistent elevated NT-proBNP; vericiguat should be prioritized over H/ISDN because her Black race is not the only qualifier and vericiguat provides residual risk reduction regardless of race; the isosorbide mononitrate must be addressed first given the cGMP pathway interaction, which is a hard contraindication to vericiguat co-administration
C) Add ivabradine 5 mg twice daily — the heart rate of 74 bpm meets the eligibility threshold (above 70 bpm), sinus rhythm is confirmed, and ivabradine is the most appropriate agent because neither H/ISDN nor vericiguat can be safely initiated while the isosorbide mononitrate is in place; ivabradine has no interaction with nitrates and can be started immediately without addressing the angina regimen
D) Add vericiguat 2.5 mg daily without addressing the isosorbide mononitrate — the cGMP interaction between vericiguat and nitrates is a caution rather than a hard contraindication, and the clinical benefit of vericiguat in this high-risk patient outweighs the theoretical vasodilation risk; the isosorbide mononitrate dose should be reduced to 15 mg daily as a precaution while monitoring blood pressure at weekly visits
E) Initiate neither agent at this visit — the patient has three potential fifth-pillar options (H/ISDN, vericiguat, ivabradine) and the complexity of her regimen, the nitrate interaction, and the angina management require multidisciplinary review with cardiology, cardiac surgery, and clinical pharmacy before any addition is made; reassess in 6 weeks after a formal medication optimization conference
ANSWER: A
Rationale:
This is a multi-constraint integration question requiring simultaneous application of eligibility criteria, drug interaction rules, and clinical priority ranking. Working through each consideration: (1) H/ISDN eligibility — met. Self-identified Black race, HFrEF, symptomatic on optimized four-pillar GDMT. This is a Class I indication. (2) Vericiguat eligibility — met. Recent worsening hospitalization within 6 months (2 months ago), elevated NT-proBNP, persistent NYHA III. This is also a supported indication. (3) Ivabradine eligibility — met. Heart rate 74 bpm above the 70 bpm threshold, sinus rhythm, LVEF 30% below 35%, NYHA III, maximally tolerated carvedilol. (4) Drug interaction constraint — the isosorbide mononitrate is the key constraint. It interacts with vericiguat (additive cGMP vasodilation — a contraindication to co-administration) but represents a different and less severe concern with H/ISDN (additive nitrate exposure, not a pharmacodynamic cGMP amplification). The H/ISDN approach requires transitioning off the isosorbide mononitrate and managing angina non-pharmacologically or with a non-nitrate agent. (5) Priority ranking: in a self-identified Black patient with HFrEF who meets the Class I H/ISDN indication, that indication is the guideline-preferred priority. The appropriate plan is to address the angina regimen (substitute isosorbide mononitrate with ranolazine or optimize carvedilol for angina), then initiate H/ISDN. Option A correctly captures all elements: H/ISDN is the priority, the nitrate must be addressed first, and a management path for the angina is identified.
Option B: Option B correctly identifies the vericiguat indication and the nitrate-vericiguat contraindication, but misstates the priority — vericiguat does not supersede the Class I H/ISDN indication in a self-identified Black patient who meets both criteria. The guideline specifically defines the Black-race H/ISDN indication as a distinct and separate Class I recommendation, and it is the higher-priority choice when the patient meets both indications, particularly given that the nitrate substitution needed for vericiguat is also needed for H/ISDN.
Option C: Option C is technically correct that ivabradine has no nitrate interaction and can be initiated without addressing the isosorbide mononitrate, but it incorrectly frames ivabradine as the most appropriate agent when a Class I H/ISDN indication is present. Selecting the agent with the fewest immediate barriers rather than the one with the strongest guideline support is a pharmacological and clinical reasoning error.
Option D: Option E:
Option D: Option D incorrectly characterizes the vericiguat-nitrate cGMP interaction as a caution rather than a contraindication and proposes nitrate dose reduction as a mitigation strategy. The VICTORIA trial explicitly excluded patients on nitrates for this reason, and the prescribing information contraindicates co-administration; dose reduction does not eliminate the pharmacodynamic synergy.
Option E: Option E is incorrect — delaying a clear clinical decision for 6 weeks for multidisciplinary review is not appropriate when the eligibility criteria are met, the drug interactions are well-characterized, and the management path is clear. In a high-risk patient with HFrEF and a recent hospitalization, therapeutic inertia carries meaningful clinical cost. A cardiologist with the relevant pharmacological knowledge can and should initiate the correct plan at this visit.
BEFORE YOU MOVE ON
Every question in this set required you to hold multiple clinical constraints simultaneously — eligibility thresholds, drug interaction rules, and competing indications — and arrive at a single defensible management decision. The integration questions near the end previewed what Tier 4 will require across extended case narratives: the same reasoning applied over four questions per patient, with each answer building on the last. The pharmacological decisions you worked through here — which intolerance qualifies for H/ISDN, which interaction makes vericiguat unsafe with nitrates, which criteria disqualify ivabradine regardless of other eligibility — are the foundation for the clinical case reasoning that defines Tier 4.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.